Zai Lab Ltd ADR (ZLAB)

Mar 26, 2025, 7:00 AM EDT - 8 days ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 13 days ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 14 days ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 22 days ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 4 weeks ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 5 weeks ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 5 weeks ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 2 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Jan 22, 2025, 11:15 PM EST - 2 months ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Jan 17, 2025, 7:30 AM EST - 2 months ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025, 7:30 AM EST - 2 months ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 10, 2025, 7:30 AM EST - 2 months ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

VRTX

Jan 10, 2025, 7:30 AM EST - 2 months ago

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

VRTX

Jan 9, 2025, 6:30 PM EST - 3 months ago

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate

Dec 26, 2024, 2:31 PM EST - 3 months ago

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 12, 2024, 7:30 AM EST - 4 months ago

Zai Lab Announces Participation in Investor Conference in January 2025

Dec 2, 2024, 7:02 AM EST - 4 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

NVCR

Nov 27, 2024, 11:05 PM EST - 4 months ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

Nov 21, 2024, 4:00 AM EST - 4 months ago

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

PFE

Nov 18, 2024, 9:15 AM EST - 4 months ago

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Nov 14, 2024, 7:43 PM EST - 5 months ago

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

Nov 13, 2024, 4:12 PM EST - 5 months ago

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Nov 12, 2024, 11:53 AM EST - 5 months ago

Zai Lab Limited (ZLAB) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 6:30 AM EST - 5 months ago

Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 11, 2024, 7:30 AM EST - 5 months ago

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

ARGX

Oct 29, 2024, 7:30 AM EDT - 5 months ago

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Oct 24, 2024, 5:15 AM EDT - 5 months ago

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Oct 18, 2024, 7:30 AM EDT - 5 months ago

Zai Lab Announces Participation in November and December Investor Conferences

Oct 17, 2024, 8:00 AM EDT - 6 months ago

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Oct 16, 2024, 7:30 AM EDT - 6 months ago

Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Sep 25, 2024, 4:36 AM EDT - 6 months ago

Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025

Sep 17, 2024, 1:32 PM EDT - 7 months ago

Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Aug 27, 2024, 8:30 AM EDT - 7 months ago

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

Aug 22, 2024, 7:30 AM EDT - 8 months ago

Zai Lab Announces Participation in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 8 months ago

Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates

Jul 16, 2024, 12:15 AM EDT - 9 months ago

Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

ARGX

Jul 15, 2024, 2:53 PM EDT - 9 months ago

Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy

Jul 10, 2024, 7:30 AM EDT - 9 months ago

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024

Jul 10, 2024, 7:30 AM EDT - 9 months ago

Aldinger Company Acquires J&J Calibrations

SGHC

Jun 11, 2024, 4:05 PM EDT - 10 months ago

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

May 22, 2024, 7:30 AM EDT - 11 months ago

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

May 20, 2024, 12:21 AM EDT - 11 months ago

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

May 16, 2024, 7:30 AM EDT - 11 months ago

Zai Lab Announces Participation in May and June Investor Conferences

May 14, 2024, 7:30 AM EDT - 11 months ago

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

May 12, 2024, 8:20 PM EDT - 11 months ago

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA

May 9, 2024, 5:18 PM EDT - 11 months ago

Zai Lab Limited (ZLAB) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:05 PM EDT - 11 months ago

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

Apr 15, 2024, 7:30 AM EDT - 1 year ago

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Zai Lab Statement on Executive Management Team's Agreement on Share Activities